Recent Publications

• Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.Robles-Oteíza C, Hastings K, Choi J, Sirois I, Ravi A, Expósito F, de Miguel F, Knight JR, López-Giráldez F, Choi H, Socci ND, Merghoub T, Awad M, Getz G, Gainor J, Hellmann MD, Caron É, Kaech SM, Politi K. J Exp Med. 2025 Jan 6; 2024 Nov 25. PMID: 39585348.
• OST Catalytic Subunit Redundancy Enables Therapeutic Targeting of N-Glycosylation.Baro M, Lee H, Kelley V, Lou R, Phoomak C, Politi K, Zeiss CJ, Van Zandt M, Contessa JN. bioRxiv. 2024 Dec 5; 2024 Dec 5. PMID: 39677793.
• Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer.Kamle S, Ma B, Schor G, Bailey M, Pham B, Cho I, Khan H, Azzoli C, Hofstetter M, Sadanaga T, Herbst R, Politi K, Lee CG, Elias JA. Transl Oncol. 2024 Nov; 2024 Aug 22. PMID: 39178575.
• Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Nat Med. 2024 Sep. PMID: 39164519.
• Overexpression of Malat1 drives metastasis through inflammatory reprogramming of the tumor microenvironment.Martinez-Terroba E, Plasek-Hegde LM, Chiotakakos I, Li V, de Miguel FJ, Robles-Oteiza C, Tyagi A, Politi K, Zamudio JR, Dimitrova N. Sci Immunol. 2024 Jun 14; 2024 Jun 14. PMID: 38875320.
• The Evolution of Mouse Models of Cancer: Past, Present, and Future.Abate-Shen C, Politi K. Cold Spring Harb Perspect Med. 2024 May 21; 2024 May 21. PMID: 38772706.
• ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.Hu B, Wiesehöfer M, de Miguel FJ, Liu Z, Chan LH, Choi J, Melnick MA, Arnal Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, Xiao A, Yan Q, Homer R, Nguyen DX, Politi K. Cancer Res. 2024 Apr 15. PMID: 38359163.
• Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma.Kim IK, Diamond MS, Yuan S, Kemp SB, Kahn BM, Li Q, Lin JH, Li J, Norgard RJ, Thomas SK, Merolle M, Katsuda T, Tobias JW, Baslan T, Politi K, Vonderheide RH, Stanger BZ. Nat Commun. 2024 Feb 20; 2024 Feb 20. PMID: 38378697.
• Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg SB. J Thorac Oncol. 2024 Feb; 2023 Oct 6. PMID: 37806385.
• Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations.Habowski AN, Budagavi DP, Scherer SD, Aurora AB, Caligiuri G, Flynn WF, Langer EM, Brody JR, Sears RC, Foggetti G, Arnal Estape A, Nguyen DX, Politi KA, Shen X, Hsu DS, Peehl DM, Kurhanewicz J, Sriram R, Suarez M, Xiao S, Du Y, Li XN, Navone NM, Labanca E, Willey CD. Cancers (Basel). 2024 Jan 29; 2024 Jan 29. PMID: 38339316.
• EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth.Kuhlmann-Hogan A, Cordes T, Xu Z, Kuna RS, Traina KA, Robles-Oteíza C, Ayeni D, Kwong EM, Levy S, Globig AM, Nobari MM, Cheng GZ, Leibel SL, Homer RJ, Shaw RJ, Metallo CM, Politi K, Kaech SM. Cancer Discov. 2024 Jan 25; 2024 Jan 25. PMID: 38270272.
• EGFR-driven lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth.Kuhlmann-Hogan A, Cordes T, Xu Z, Kuna RS, Traina KA, Robles-Oteiza C, Ayeni D, Kwong EM, Levy S, Globig AM, Nobari MM, Cheng GZ, Leibel SL, Homer RJ, Shaw RJ, Metallo CM, Politi K, Kaech SM. Cancer Discov. 2024 Jan 19; 2024 Jan 19. PMID: 38241033.
• The New NCI Precision Medicine Trials.Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, Chen HX, Ivy SP, Korde LA, Little RF, McShane LM, Moscow JA, Patton DR, Thurin M, Yee LM, Doroshow JH. Clin Cancer Res. 2023 Dec 1. PMID: 37531248.
• Oncogenic context shapes the fitness landscape of tumor suppression.Blair LM, Juan JM, Sebastian L, Tran VB, Nie W, Wall GD, Gerceker M, Lai IK, Apilado EA, Grenot G, Amar D, Foggetti G, Do Carmo M, Ugur Z, Deng D, Chenchik A, Paz Zafra M, Dow LE, Politi K, MacQuitty JJ, Petrov DA, Winslow MM, Rosen MJ, Winters IP. Nat Commun. 2023 Oct 12; 2023 Oct 12. PMID: 37828026.
• Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, Cai WL, Melnick MA, Robles-Oteiza C, Hinkley MM, Tsai JA, Hartley AV, Wei J, Wurtz A, Li F, Toki MI, Rimm DL, Homer R, Wilen CB, Xiao AZ, Qi J, Yan Q, Nguyen DX, Jänne PA, Kadoch C, Politi KA. Cancer Cell. 2023 Aug 14; 2023 Aug 3. PMID: 37541244.
• Effect of Dietary Supplementation with a Mixture of Natural Antioxidants on Milk Yield, Composition, Oxidation Stability and Udder Health in Dairy Ewes.Karageorgou A, Tsafou M, Goliomytis M, Hager-Theodorides A, Politi K, Simitzis P. Antioxidants (Basel). 2023 Aug 6; 2023 Aug 6. PMID: 37627566.
• PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. Cancer Res. 2023 Aug 1. PMID: 37311042.
• Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment.Chiorazzi M, Martinek J, Krasnick B, Zheng Y, Robbins KJ, Qu R, Kaufmann G, Skidmore Z, Juric M, Henze LA, Brösecke F, Adonyi A, Zhao J, Shan L, Sefik E, Mudd J, Bi Y, Goedegebuure SP, Griffith M, Griffith O, Oyedeji A, Fertuzinhos S, Garcia-Milian R, Boffa D, Detterbeck F, Dhanasopon A, Blasberg J, Judson B, Gettinger S, Politi K, Kluger Y, Palucka K, Fields RC, Flavell RA. J Immunother Cancer. 2023 Jul. PMID: 37487666.
• Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy.Kim IK, Diamond M, Yuan S, Kemp S, Li Q, Lin J, Li J, Norgard R, Thomas S, Merolle M, Katsuda T, Tobias J, Politi K, Vonderheide R, Stanger B. Res Sq. 2023 Jun 1; 2023 Jun 1. PMID: 37398248.
• Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.Grant MJ, Aredo JV, Starrett JH, Stockhammer P, van Alderwerelt van Rosenburgh IK, Wurtz A, Piper-Valillo AJ, Piotrowska Z, Falcon C, Yu HA, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li FY, Neal J, Lemmon MA, Walther Z, Politi K, Goldberg SB. Clin Cancer Res. 2023 Jun 1. PMID: 36913537.
• An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1.Aftab F, Rodriguez-Fuguet A, Silva L, Kobayashi IS, Sun J, Politi K, Levantini E, Zhang W, Kobayashi SS, Zhang WC. Br J Cancer. 2023 May; 2023 Feb 21. PMID: 36810913.
• EGFR (+) lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth.Kuhlmann-Hogan A, Cordes T, Xu Z, Traina KA, Robles-Oteíza C, Ayeni D, Kwong EM, Levy SR, Nobari M, Cheng GZ, Shaw R, Leibel SL, Metallo CM, Politi K, Kaech SM. bioRxiv. 2023 Apr 17; 2023 Apr 17. PMID: 37131637.
• Challenges and opportunities for modeling aging and cancer.Anczuków O, Airhart S, Chuang JH, Coussens LM, Kuchel GA, Korstanje R, Li S, Lucido AL, McAllister SS, Politi K, Polyak K, Ratliff T, Ren G, Trowbridge JJ, Ucar D, Palucka K. Cancer Cell. 2023 Apr 10; 2023 Mar 30. PMID: 37001528.
• Overexpressed Malat1 Drives Metastasis through Inflammatory Reprogramming of Lung Adenocarcinoma Microenvironment.Mart Nez-Terroba E, de Miguel FJ, Li V, Robles-Oteiza C, Politi K, Zamudio JR, Dimitrova N. bioRxiv. 2023 Mar 23; 2023 Mar 23. PMID: 36993368.
• Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer.Adua SJ, Arnal-Estapé A, Zhao M, Qi B, Liu ZZ, Kravitz C, Hulme H, Strittmatter N, López-Giráldez F, Chande S, Albert AE, Melnick MA, Hu B, Politi K, Chiang V, Colclough N, Goodwin RJA, Cross D, Smith P, Nguyen DX. Nat Commun. 2022 Dec 12; 2022 Dec 12. PMID: 36509758.
• A path to translation: How 3D patient tumor avatars enable next generation precision oncology.Bose S, Barroso M, Chheda MG, Clevers H, Elez E, Kaochar S, Kopetz SE, Li XN, Meric-Bernstam F, Meyer CA, Mou H, Naegle KM, Pera MF, Perova Z, Politi KA, Raphael BJ, Robson P, Sears RC, Tabernero J, Tuveson DA, Welm AL, Welm BE, Willey CD, Salnikow K, Chuang JH, Shen X. Cancer Cell. 2022 Dec 12; 2022 Oct 20. PMID: 36270276.
• YES1 Is a Druggable Oncogenic Target in SCLC.Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, Echepare M, Exposito F, Serrano D, Ferrer I, Nunez-Buiza A, Garmendia I, García-Pedrero JM, Gurpide A, Paz-Ares L, Politi K, Montuenga LM, Calvo A. J Thorac Oncol. 2022 Dec; 2022 Aug 18. PMID: 35988891.
• Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.van Alderwerelt van Rosenburgh IK, Lu DM, Grant MJ, Stayrook SE, Phadke M, Walther Z, Goldberg SB, Politi K, Lemmon MA, Ashtekar KD, Tsutsui Y. Nat Commun. 2022 Nov 10; 2022 Nov 10. PMID: 36357385.
• Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Clin Cancer Res. 2022 Sep 1. PMID: 35713632.
• Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment.Papadas A, Deb G, Cicala A, Officer A, Hope C, Pagenkopf A, Flietner E, Morrow ZT, Emmerich P, Wiesner J, Arauz G, Bansal V, Esbona K, Capitini CM, Matkowskyj KA, Deming DA, Politi K, Abrams SI, Harismendy O, Asimakopoulos F. Cell Rep. 2022 Aug 16. PMID: 35977482.
• Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Nat Commun. 2022 Aug 8; 2022 Aug 8. PMID: 35941179.
• Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Nat Commun. 2022 Jul 26; 2022 Jul 26. PMID: 35882862.
• A group approach to growing as a principal investigator.Greco V, Politi K, Eisenbarth S, Colón-Ramos D, Giraldez AJ, Bewersdorf J, Berg DN. Curr Biol. 2022 Jun 6. PMID: 35671717.
• Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.Tu E, McGlinchey K, Wang J, Martin P, Ching SL, Floc'h N, Kurasawa J, Starrett JH, Lazdun Y, Wetzel L, Nuttall B, Ng FS, Coffman KT, Smith PD, Politi K, Cooper ZA, Streicher K. JCI Insight. 2022 Feb 8; 2022 Feb 8. PMID: 35132961.
• Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma.Leitner BP, Givechian KB, Ospanova S, Beisenbayeva A, Politi K, Perry RJ. NPJ Precis Oncol. 2022 Jan 27; 2022 Jan 27. PMID: 35087143.
• Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment.Foggetti G, Li C, Cai H, Petrov DA, Winslow MM, Politi K. Mol Cell Oncol. 2022; 2022 Jan 14. PMID: 35252550.
• Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein.Tripathi BK, Anderman MF, Bhargava D, Boccuzzi L, Qian X, Wang D, Durkin ME, Papageorge AG, de Miguel FJ, Politi K, Walters KJ, Doroshow JH, Lowy DR. Nat Commun. 2021 Dec 3; 2021 Dec 3. PMID: 34862367.
• Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development.Arnal-Estapé A, Foggetti G, Starrett JH, Nguyen DX, Politi K. Cold Spring Harb Perspect Med. 2021 Dec 1; 2021 Dec 1. PMID: 34518338.
• Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma.Robles-Oteiza C, Ayeni D, Levy S, Homer RJ, Kaech SM, Politi K. Dis Model Mech. 2021 Nov 1; 2021 Nov 15. PMID: 34494649.
• Cycling cancer persister cells arise from lineages with distinct programs.Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hütter JC, Hu B, Thakore PI, Tabaka M, Fulco CP, Colgan W, Cuevas BM, Hurvitz SA, Slamon DJ, Deik A, Pierce KA, Clish C, Hata AN, Zaganjor E, Lahav G, Politi K, Brugge JS, Regev A. Nature. 2021 Aug; 2021 Aug 11. PMID: 34381210.
• Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo.Foggetti G, Li C, Cai H, Hellyer JA, Lin WY, Ayeni D, Hastings K, Choi J, Wurtz A, Andrejka L, Maghini DG, Rashleigh N, Levy S, Homer R, Gettinger SN, Diehn M, Wakelee HA, Petrov DA, Winslow MM, Politi K. Cancer Discov. 2021 Jul; 2021 Mar 11. PMID: 33707235.
• Genetic Diversity and Epidemiological Significance of Wild Boar HEV-3 Strains Circulating in Poland.Kozyra I, Bigoraj E, Jabłoński A, Politi K, Rzeżutka A. Viruses. 2021 Jun 19; 2021 Jun 19. PMID: 34205456.
• Hesperidin and Naringin Improve Broiler Meat Fatty Acid Profile and Modulate the Expression of Genes Involved in Fatty Acid β-oxidation and Antioxidant Defense in a Dose Dependent Manner.Hager-Theodorides AL, Massouras T, Simitzis PE, Moschou K, Zoidis E, Sfakianaki E, Politi K, Charismiadou M, Goliomytis M, Deligeorgis S. Foods. 2021 Mar 31; 2021 Mar 31. PMID: 33807218.
• Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.Wei J, Alfajaro MM, DeWeirdt PC, Hanna RE, Lu-Culligan WJ, Cai WL, Strine MS, Zhang SM, Graziano VR, Schmitz CO, Chen JS, Mankowski MC, Filler RB, Ravindra NG, Gasque V, de Miguel FJ, Patil A, Chen H, Oguntuyo KY, Abriola L, Surovtseva YV, Orchard RC, Lee B, Lindenbach BD, Politi K, van Dijk D, Kadoch C, Simon MD, Yan Q, Doench JG, Wilen CB. Cell. 2021 Jan 7; 2020 Oct 20. PMID: 33147444.
• Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR. J Clin Oncol. 2020 Dec 1; 2020 Oct 6. PMID: 33021871.
• Deconstructing tumor heterogeneity: the stromal perspective.Vickman RE, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, Deng WM, Granneman JG, Hildesheim J, Kalluri R, Lau KS, Lengyel E, Lundeberg J, Moscat J, Nelson PS, Pietras K, Politi K, Puré E, Scherz-Shouval R, Sherman MH, Tuveson D, Weeraratna AT, White RM, Wong MH, Woodhouse EC, Zheng Y, Hayward SW, Stewart SA. Oncotarget. 2020 Oct 6; 2020 Oct 6. PMID: 33088423.
• Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection.Wei J, Alfajaro MM, Hanna RE, DeWeirdt PC, Strine MS, Lu-Culligan WJ, Zhang SM, Graziano VR, Schmitz CO, Chen JS, Mankowski MC, Filler RB, Gasque V, de Miguel F, Chen H, Oguntuyo K, Abriola L, Surovtseva YV, Orchard RC, Lee B, Lindenbach B, Politi K, van Dijk D, Simon MD, Yan Q, Doench JG, Wilen CB. bioRxiv. 2020 Jun 17; 2020 Jun 17. PMID: 32869025.
• Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech SM, Unni AM, Homer R, Lockwood WW, Michor F, Goldberg SB, Lemmon MA, Smith PD, Cross DAE, Politi K. Cancer Res. 2020 May 15; 2020 Mar 19. PMID: 32193290.
• Leveraging Patient-Derived Models for Immunotherapy Research.Politi K. Am Soc Clin Oncol Educ Book. 2020 May. PMID: 32511030.
• Assessment of IFNγ responsiveness in patient-derived xenografts.Cardenas JJ, Robles-Oteiza C, Politi K. Methods Enzymol. 2020; 2019 Dec 9. PMID: 31948560.
• The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.Truini A, Starrett JH, Stewart T, Ashtekar K, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. Clin Cancer Res. 2019 Nov 1; 2019 Jun 10. PMID: 31182434.
• The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I. J Immunother Cancer. 2019 Aug 15; 2019 Aug 15. PMID: 31416487.
• Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA. Clin Cancer Res. 2019 Aug 1; 2019 May 3. PMID: 31053602.
• Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Clin Cancer Res. 2019 Aug 1; 2019 Mar 1. PMID: 30824587.
• Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, Kaech S, Politi K. J Immunother Cancer. 2019 Jul 10; 2019 Jul 10. PMID: 31291990.
• Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. J Immunother Cancer. 2019 Jul 4; 2019 Jul 4. PMID: 31272507.
• Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. J Immunother Cancer. 2019 May 22; 2019 May 22. PMID: 31113486.
• Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis.Wingrove E, Liu ZZ, Patel KD, Arnal-Estapé A, Cai WL, Melnick MA, Politi K, Monteiro C, Zhu L, Valiente M, Kluger HM, Chiang VL, Nguyen DX. Cell Rep. 2019 Apr 23. PMID: 31018140.
• miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, Melnick MA, Politi K, Asara JM, Costa DB, Bult CJ, Slack FJ. Nat Metab. 2019 Apr; 2019 Apr 8. PMID: 31535082.
• YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M. Proc Natl Acad Sci U S A. 2018 Jun 26; 2018 Jun 6. PMID: 29875142.
• ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation.Wilson FH, Politi K. Cancer Discov. 2018 Jun. PMID: 29858224.
• Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS. J Thorac Oncol. 2018 Jun; 2018 Mar 22. PMID: 29578107.
• Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Nat Med. 2018 May; 2018 Apr 23. PMID: 29686424.
• Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger SN, Wilson LD, Herbst RS, Patel AA. Clin Cancer Res. 2018 Apr 15; 2018 Jan 12. PMID: 29330207.
• The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. Clin Cancer Res. 2018 Mar 1; 2017 Dec 7. PMID: 29217530.
• Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Cancer Discov. 2017 Dec; 2017 Oct 12. PMID: 29025772.
• Genome-Wide RNA Interference: Functional Genomics in the Postgenomics Era.Politi K, Wajapeyee N. Cold Spring Harb Protoc. 2017 Sep 1; 2017 Sep 1. PMID: 28864574.
• Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR. Lung Cancer. 2017 Jul; 2017 Apr 19. PMID: 28577937.
• Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.Suda K, Rozeboom L, Furugaki K, Yu H, Melnick MAC, Ellison K, Rivard CJ, Politi K, Mitsudomi T, Hirsch FR. Biomed Res Int. 2017; 2017 Oct 8. PMID: 29119113.
• Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.McFadden DG, Politi K, Bhutkar A, Chen FK, Song X, Pirun M, Santiago PM, Kim-Kiselak C, Platt JT, Lee E, Hodges E, Rosebrock AP, Bronson RT, Socci ND, Hannon GJ, Jacks T, Varmus H. Proc Natl Acad Sci U S A. 2016 Oct 18; 2016 Oct 4. PMID: 27702896.
• PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?Gettinger S, Politi K. Clin Cancer Res. 2016 Sep 15; 2016 Jul 28. PMID: 27470969.
• Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.Forloni M, Gupta R, Nagarajan A, Sun LS, Dong Y, Pirazzoli V, Toki M, Wurtz A, Melnick MA, Kobayashi S, Homer RJ, Rimm DL, Gettinger SJ, Politi K, Dogra SK, Wajapeyee N. Cell Rep. 2016 Jul 12; 2016 Jun 23. PMID: 27346347.
• Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.Pirazzoli V, Ayeni D, Meador CB, Sanganahalli BG, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K. Clin Cancer Res. 2016 Jan 15; 2015 Sep 4. PMID: 26341921.
• Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.Ayeni D, Politi K, Goldberg SB. Clin Cancer Res. 2015 Sep 1; 2015 Jul 13. PMID: 26169963.
• The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.Politi K, Ayeni D, Lynch T. Cancer Cell. 2015 Jun 8. PMID: 26058074.
• Lung cancer in the era of precision medicine.Politi K, Herbst RS. Clin Cancer Res. 2015 May 15. PMID: 25979927.
• EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.Morgensztern D, Politi K, Herbst RS. JAMA Oncol. 2015 May. PMID: 26181013.
• Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, Varmus HE, Guha U. Cancer Discov. 2015 May; 2015 Mar 3. PMID: 25735773.
• Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas.Bantikassegn A, Song X, Politi K. Am J Respir Cell Mol Biol. 2015 Apr. PMID: 25347711.
• ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.Song X, Fan PD, Bantikassegn A, Guha U, Threadgill DW, Varmus H, Politi K. Cancer Res. 2015 Mar 15; 2015 Jan 16. PMID: 25596284.
• Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W. Mol Cancer Ther. 2015 Feb; 2014 Dec 4. PMID: 25477325.
• Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.Politi K, Gettinger S. Clin Cancer Res. 2014 Nov 15; 2014 Sep 16. PMID: 25228532.
• Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K. Cell Rep. 2014 May 22; 2014 May 9. PMID: 24813888.
• Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J. Cancer Discov. 2014 May; 2014 Feb 17. PMID: 24535670.
• MYCxing it up with FGFR1 in squamous cell lung cancer.Lockwood W, Politi K. Cancer Discov. 2014 Feb. PMID: 24501305.
• Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse.Pirazzoli V, Politi K. Cold Spring Harb Protoc. 2014 Feb 1; 2014 Feb 1. PMID: 24492774.
• Translational therapeutics in genetically engineered mouse models of cancer.Olive KP, Politi K. Cold Spring Harb Protoc. 2014 Feb 1; 2014 Feb 1. PMID: 24492770.
• De novo selection of oncogenes.Chacón KM, Petti LM, Scheideman EH, Pirazzoli V, Politi K, DiMaio D. Proc Natl Acad Sci U S A. 2014 Jan 7; 2013 Dec 16. PMID: 24344264.
• DOK2 inhibits EGFR-mutated lung adenocarcinoma.Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP. PLoS One. 2013; 2013 Nov 8. PMID: 24255704.
• Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Genome Res. 2013 Sep; 2013 Jun 3. PMID: 23733853.
• Noncovalent wild-type-sparing inhibitors of EGFR T790M.Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J. Cancer Discov. 2013 Feb; 2012 Dec 10. PMID: 23229345.
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W. Cancer Discov. 2012 Oct; 2012 Sep 5. PMID: 22956644.
• Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, Difeo A, Narla G. J Clin Invest. 2012 Jul; 2012 Jun 1. PMID: 22653055.
• Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.Politi K, Lynch TJ. Clin Cancer Res. 2012 Mar 15; 2012 Feb 8. PMID: 22317760.
• Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, Depinho RA, Kemp CJ, Varmus HE, Hanash SM. Cancer Cell. 2011 Sep 13. PMID: 21907921.
• How genetically engineered mouse tumor models provide insights into human cancers.Politi K, Pao W. J Clin Oncol. 2011 Jun 1; 2011 Jan 24. PMID: 21263096.
• Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.Politi K, Fan PD, Shen R, Zakowski M, Varmus H. Dis Model Mech. 2010 Jan-Feb; 2009 Dec 9. PMID: 20007486.
• Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, Getlik M, Heukamp LC, Ansén S, Zander T, Beroukhim R, Kashkar H, Shokat KM, Sellers WR, Rauh D, Orr C, Hoeflich KP, Friedman L, Wong KK, Pao W, Thomas RK. Proc Natl Acad Sci U S A. 2009 Oct 27; 2009 Oct 5. PMID: 19805051.
• Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W. J Clin Invest. 2009 Oct; 2009 Sep 14. PMID: 19759520.
• Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras.Podsypanina K, Politi K, Beverly LJ, Varmus HE. Proc Natl Acad Sci U S A. 2008 Apr 1; 2008 Mar 20. PMID: 18356293.